TESTING (final results) (2022) — Trial Summary

TESTING (final results) (2022): Final report of the TESTING trial (n=503) of oral methylprednisolone versus placebo in IgA nephropathy with proteinuria ≥1 g/day. The first 262 participants were randomized under the full-dose regimen (0.6–0.8 mg/kg/day; 136 methylprednisolone, 126 placebo); after exc

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.